Almaject Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Almaject Pharmaceutical Import Records from India — 2 Products, $1.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Almaject — Pharmaceutical Importer Profile (2026) | 2 Products, $1.3M Trade | TransData Nexus

Almaject

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $1.3M Total Trade · DGFT Verified

Almaject is a pharmaceutical importer based in United States with a total trade value of $1.3M across 2 products in 2 therapeutic categories. Based on 26 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Almaject sources from 1 verified Indian supplier, with Gland Pharma Limited accounting for 100.0% of imports.

Almaject — Import Portfolio & Supplier Network

Almaject import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Almaject?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gland Pharma Limited	$7.2M	152	100.0%

Almaject sources from 1 verified Indian supplier across 27 distinct formulations. The sourcing is highly concentrated — Gland Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Almaject Import?

Formulation	Value	Ships
Ketorolac tromethamine injection USP	$1.4M	29
Labetalol hcl injection USP	$1.3M	27
Vancomycin hydrochloride for injection	$1.0M	22
Rocuronium bromide injection 10MG/ML	$550.0K	11
Ketorolac tromethamine injection USP	$400.0K	8
Dexrazoxane for injection	$360.6K	8
Ketorolac tromethamine injection USP	$350.0K	7
Labetalol hydrochloride injection USP	$200.0K	4
Caspofungin acetate for injection	$150.0K	3
Labetalol hcl injection USP 100MG/20ML	$138.7K	3
Metoprolol tartrate injection 5MG/5ML (1MG/ML)	$126.0K	3
Metoprolol tartrate injection 5MG 5ML 1MG ML	$102.9K	3
Labetalol hydrochloride injection USP	$102.2K	3
Rocuronium bromide injection 100MG/10ML	$100.0K	2
Voriconazole for injection 200MG/vial	$100.0K	2

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ketorolac	Analgesics & Antipyretics	$1.2M	24	1.0%	7
2	Voriconazole	Advanced Antifungals	$100.0K	2	0.3%	10

Almaject imports 2 pharmaceutical products across 2 categories into United States totaling $1.3M.

Almaject — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Almaject, Inc. is a U.S.-based pharmaceutical company specializing in the development, acquisition, and commercialization of injectable generic pharmaceutical products. Established in 2020, Almaject is headquartered in Morristown, New Jersey. It operates as a subsidiary of Alvogen, a global, privately owned pharmaceutical company that focuses on generic, brand, over-the-counter (OTC), and biosimilar products.

Almaject's portfolio encompasses a broad range of therapeutic areas, with a particular emphasis on injectable formulations. The company's mission is to provide affordable and accessible injectable medications to the acute and alternate-site healthcare markets in the United States. By leveraging Alvogen's global infrastructure and expertise, Almaject aims to enhance the availability of essential injectable drugs, thereby contributing to the overall efficiency and effectiveness of the U.S. pharmaceutical distribution network.

2Distribution Network

Almaject's distribution network is strategically designed to ensure the efficient delivery of its injectable pharmaceutical products across the United States. While specific warehouse locations are not publicly disclosed, the company's operations are supported by Alvogen's extensive global infrastructure, which includes manufacturing and development hubs in the U.S., Romania, Korea, and Taiwan. This expansive network facilitates streamlined logistics and timely distribution of Almaject's products to various healthcare facilities nationwide.

The company's logistics capabilities are further enhanced by its partnership with Alvogen, enabling access to a robust supply chain and distribution channels. This collaboration ensures that Almaject can effectively meet the demands of the U.S. healthcare market, providing a reliable source of injectable generic pharmaceuticals to hospitals, clinics, and other medical institutions.

3Industry Role

Almaject plays a pivotal role in the U.S. pharmaceutical supply chain as a specialized importer and distributor of injectable generic medications. By focusing exclusively on injectable formulations, Almaject addresses a critical segment of the market, ensuring the availability of essential drugs for acute and alternate-site healthcare settings. This specialization allows the company to cater to the unique needs of healthcare providers and patients requiring injectable therapies.

In its capacity as an importer, Almaject sources finished pharmaceutical formulations from international suppliers, particularly from India, to meet the specific demands of the U.S. market. This strategic sourcing approach enables Almaject to offer a diverse range of injectable products, thereby enhancing the overall efficiency and effectiveness of the U.S. pharmaceutical distribution network.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Almaject

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Almaject's sourcing strategy exhibits a high degree of concentration, with a significant reliance on a single supplier for its injectable pharmaceutical products. According to TransData Nexus proprietary trade data, Almaject has imported a total of $1.3 million worth of finished pharmaceutical formulations from India over 26 shipments, with 100% of these imports originating from GLAND PHARMA LIMITED.

This single-source dependency presents both opportunities and risks. On one hand, a concentrated sourcing strategy can lead to streamlined operations and potentially more favorable terms with the supplier. On the other hand, it exposes Almaject to supply chain vulnerabilities, such as disruptions due to geopolitical issues, regulatory changes, or operational challenges faced by the supplier.

The shipment data indicates a consistent and stable relationship between Almaject and GLAND PHARMA LIMITED, suggesting a reliable supply chain. However, the lack of diversification in sourcing could pose challenges in the event of unforeseen disruptions. To mitigate potential risks, Almaject may consider exploring additional suppliers or developing contingency plans to ensure the uninterrupted availability of its injectable products.

2Supply Chain Resilience

Almaject's supply chain resilience is closely tied to its sourcing strategy, which currently relies exclusively on GLAND PHARMA LIMITED for injectable pharmaceutical products. This single-source dependency means that any disruptions affecting GLAND PHARMA LIMITED could directly impact Almaject's ability to supply products to the U.S. market.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the pharmaceutical industry. The FDA is responsible for ensuring the safety, efficacy, and quality of drugs imported into the U.S. market. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA) and the Drug Enforcement Administration (DEA) regulations.

For Indian pharmaceutical companies seeking to export to the U.S., obtaining FDA approval is mandatory. This process involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for generics, which includes comprehensive data on the drug's safety, efficacy, manufacturing processes, and labeling. The FDA evaluates these submissions to ensure compliance with U.S. standards before granting marketing authorization.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. are stringent. Indian exporters must ensure that their manufacturing facilities are registered with the FDA and comply with Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S).

Almaject — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Almaject's product strategy focuses on injectable generic pharmaceuticals, specifically targeting therapeutic areas such as analgesics, antipyretics, and advanced antifungals. The company's emphasis on these categories aligns with the growing demand for injectable medications in acute and alternate-site healthcare settings. Injectable drugs are often preferred in critical care situations due to their rapid onset of action and precise dosing capabilities.

The market demand for these products is driven by the need for effective pain management, fever reduction, and treatment of serious infections. By

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Almaject

What products does Almaject import from India?

Almaject imports 2 pharmaceutical products across 2 categories. Top imports: Ketorolac ($1.2M), Voriconazole ($100.0K).

Who supplies pharmaceuticals to Almaject from India?

Almaject sources from 1 verified Indian suppliers. The primary supplier is Gland Pharma Limited (100.0% of imports, $7.2M).

What is Almaject's total pharmaceutical import value?

Almaject's total pharmaceutical import value from India is $1.3M, based on 26 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Almaject focus on?

Almaject imports across 2 categories. The largest: Analgesics & Antipyretics (92.3%), Advanced Antifungals (7.7%).

Get Full Almaject Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.